Stock CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Creative Medical Technology Holdings, Inc.

Equities

CELZ

US22529Y4089

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
4.82 USD -0.21% Intraday chart for Creative Medical Technology Holdings, Inc. -7.31% +4.56%
Mar. 22 Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023. CI
Mar. 22 Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Creative Medical Technology Holdings, Inc.

Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023. CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201 DJ
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access CI
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise MT
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures MT
Creative Medical Shares Rally Premarket on FDA Orphan Designation DJ
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony MT
Top Premarket Gainers MT
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem CI
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023. CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain CI
Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem? (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain CI
Top Premarket Gainers MT
Top Premarket Gainers MT
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023. CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Top Premarket Decliners MT
Creative Medical Technology Holdings, Inc. announces an Equity Buyback for $2 million worth of its shares. CI
Creative Medical Technology Holdings, Inc. authorizes a Buyback Plan. CI
Creative Medical to Trade on 1-for-10 Reverse Stock-Split Basis Starting Monday MT
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform CI
Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development CI
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line CI

Chart Creative Medical Technology Holdings, Inc.

Chart Creative Medical Technology Holdings, Inc.
More charts

Company Profile

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
4.83 USD
Average target price
30 USD
Spread / Average Target
+521.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock Creative Medical Technology Holdings, Inc.
+4.56% 6.55M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.49% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.31% 96.73B
ARGENX SE Stock argenx SE
+1.66% 21.31B
BIONTECH SE Stock BioNTech SE
-16.16% 21.21B
GENMAB A/S Stock Genmab A/S
-6.82% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.41% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-22.87% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.32% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.46% 10.98B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CELZ Stock
  4. News Creative Medical Technology Holdings, Inc.
  5. Top Midday Gainers